Esophageal malignancy: A growing concern

Jianyuan Chai, M Mazen Jamal

Abstract

Esophageal cancer is mainly found in Asia and east Africa and is one of the deadliest cancers in the world. However, it has not garnered much attention in the Western world due to its low incidence rate. An increasing amount of data indicate that esophageal cancer, particularly esophageal adenocarcinoma, has been rising by 6-fold annually and is now becoming the fastest growing cancer in the United States. This rise has been associated with the increase of the obese population, as abdominal fat puts extra pressure on the stomach and causes gastroesophageal reflux disease (GERD). Long standing GERD can induce esophagitis and metaplasia and, ultimately, leads to adenocarcinoma. Acid suppression has been the main strategy to treat GERD; however, it has not been proven to control esophageal malignancy effectively. In fact, its side effects have triggered multiple warnings from regulatory agencies. The high mortality and fast growth of esophageal cancer demand more vigorous efforts to look into its deeper mechanisms and come up with better therapeutic options.

Key words: Esophageal cancer; Gastroesophageal reflux disease; Obesity

Peer reviewers: Hiroshi Nakagawa, Assistant Professor, Gastroenterology Division, University of Pennsylvania, 415 Curie Blvd., 638B CRB, Philadelphia, PA 19104, United States; Piero Marco Fisichella, MD, Department of Surgery, Loyola University Medical Center, 2160 S. 1st Ave, Maywood, IL 60153, United States; Rene Lambert, Professor, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Cedex 8 Lyon, France


INTRODUCTION

While the incidence of most cancers is declining, esophageal cancer has been continuing its march as the fastest growing malignancy in the Western world[1,2]. This rise is largely derived from gastroesophageal reflux disease (GERD), which is associated with the proliferation of obesity. The continuous growth of the obese population foreshadows a future increase of GERD and its associated esophageal cancer. This demands immediate and more rigorous research on the molecular mechanisms of this common disease and its pathways which lead to esophageal malignancy. Current GERD treatment mainly relies on acid suppression drugs which have not been proved to change the risk of cancer development. Although the debate is still going on whether gastric acid or bile acid is ultimately responsible for GERD malignancy, based on the data from human studies, animal modeling, and in vitro simulation, perhaps it is time to explore other options.

STATISTICS OF ESOPHAGEAL CANCER: RISING NUMBERS

Cancer is the second leading cause of death in the world[18].
Chai J et al. Esophageal malignancy

after heart disease (21.09%), contributing 18.04% to the total number of deaths worldwide (Figure 1). Among all types of cancers, skin cancer is the most common one, which includes 2-3 million non-melanoma and 132,000 melanoma cases diagnosed each year, making up one third of the total cancer cases. According to Skin Cancer Foundation Statistics, one in every five Americans will develop skin cancer in their lifetime. This prevalence is largely due to depletion of ozone in the atmosphere, which weakens our planet's protective shield from the brunt of the sun's harmful rays. It is estimated that every 10% decrease in ozone levels will generate an additional 300,000 non-melanoma and 4500 melanoma cancer cases. However, the majority of skin cancer can be easily treated, while digestive cancers, such as esophageal cancer, are highly life-threatening.

Esophageal cancer is found more commonly in males than in females, with a ratio of approximately 7:1. Currently, it is the 7th leading cancer in men globally, contributing 6.51% to the total number of male cancer cases (Figure 2). There are two main subtypes of esophageal cancer: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC occurs most often in the middle portion of the esophagus and accounts for 90%-95% of all cases of esophageal cancer worldwide, while EAC is primarily found in the lower esophagus. The type and incidence of esophageal cancer varies dramatically depending on the geographical location (Figure 3). The top 10 countries with the highest age-standardized death rate due to esophageal cancer are Nauru (30.3), Sao Tome (26.4), Mongolia (18.6), South Africa (18.2), Malawi (18.2), China (15.5), Lesotho (15.5), Kenya (13.9), Mozambique (13.5) and Uganda (13.4) (the death rate being deaths per 100,000 people). The highest rates are found in Asia, stretching from northern Iran through the central Asian republics to north-central China, often referred to as the “esophageal cancer belt”. For instance, in China, the majority of esophageal cancer diagnoses are ESCC and it is ranked as the 8th leading cause of death nationwide (Table 1), mostly in northern China where the incidence rate can be as high as 800 cases per 100,000 people. On the other hand, in the United States, more than 50% of esophageal cancer cases are EAC, and the rate is less than 5 in 100,000, making it the 29th leading cause of death. For this reason, esophageal cancer is not even on the current list of common cancers in the United States, according to the National Cancer Institute. In order to be on the list, esophageal cancer has to have at least 40,000 cases a year, while the current estimate for 2012 is only 17,460. Although the reason for this geographic variation still needs investigation, several factors have been suggested that might all contribute to the issue to a certain degree, such as Helicobacter infection, dietary pattern, and life habits.[4] As Eastern and Western countries become increasingly open to each other and people adapt more to each other, we expect this discrepancy will become less and less. As evident in China, EAC incidence was doubled from the 1970s to the 1980s, according to an examination of the medical records of esophageal cancer patients diagnosed from 1970 to 2001 in a local hospital.[5]

These numbers only tell one side of the story. Based on the annual reports on the status of cancer[6,7], although esophageal cancer is low in Americans, it has been rising by 6-fold annually and its increase rate now exceeds that
for any other type of cancer. There are several possible reasons for this rise, such as excessive alcohol consumption, smoking, stress, and a diet low in vegetables, but the leading factor is GERD, a term that frequently appears in the media as well as in general conversations. A recent study showed that GERD increases the risk of esophageal cancer by 8.6 fold.

GERD: NOT A SMALL PROBLEM
GERD is the most common gastrointestinal diagnosis given during office visits and its direct medical costs, which primarily include drug costs, exceed $10 billion a year in the United States, whereas indirect costs resulting from reduced work productivity are estimated to be as much as $75 billion a year. GERD occurs when the esophageal sphincter at the bottom of the esophagus weakens and allows stomach acid (often mixed with duodenal contents) to back up into the esophagus. The refluxate erodes the epithelial lining of the lower esophagus and gives a burning sensation in the middle of the chest, which is commonly described as “heartburn”. Patients with long standing GERD can develop esophagitis, an inflammation characterized histologically by a markedly thickened epithelium, elongation of the lamina propria papillae into the epithelium, and basal cell hyperplasia (Figure 4). Over time, this inflammation/injury cycle can induce esophageal mucosa transformation from squamous to a more protective intestinal columnar phenotype, known as Barrett’s esophagus (BE). From a physiological point of view, the secretory columnar epithelium is better prepared to withstand the erosive action of the acidic refluxate than squamous epithelium; however, this metaplastic change confers an increased risk of transformation to EAC. Studies have shown that people with BE can have as high as a 400-fold increased risk of EAC.

OBESITY: THE DEVIL
The rise in GERD is associated with the rapidly growing obese population, which is usually measured by body mass index (BMI). BMI is calculated based on the weight and height of a person $[\text{BMI} = \text{weight} / (\text{height})^2, \text{kg/m}^2]$. The World Health Organization regards a BMI of less than 18.5 as underweight and may indicate malnutrition, an eating disorder, or other health problems, while a BMI greater than 25 is considered overweight and above 30 is considered obese. A recent study showed that global obe-
Esophageal cancer is the No. 8 killer in China, while in the United States, it is No. 29. Here the death rate is the percentage of the total deaths nationwide. Data from World Health Organization, World Bank and National Institute of Health.

<table>
<thead>
<tr>
<th>Rank</th>
<th>Diseases</th>
<th>China</th>
<th>United States</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Deaths</td>
<td>Death rate (%)</td>
</tr>
<tr>
<td>1</td>
<td>Stroke</td>
<td>2 125 802</td>
<td>23.92</td>
</tr>
<tr>
<td>2</td>
<td>Lung disease</td>
<td>1 287 089</td>
<td>14.48</td>
</tr>
<tr>
<td>3</td>
<td>Coronary heart disease</td>
<td>1 040 692</td>
<td>11.71</td>
</tr>
<tr>
<td>4</td>
<td>Lung cancers</td>
<td>460 856</td>
<td>5.19</td>
</tr>
<tr>
<td>5</td>
<td>Liver cancer</td>
<td>380 491</td>
<td>4.28</td>
</tr>
<tr>
<td>6</td>
<td>Stomach cancer</td>
<td>354 829</td>
<td>3.99</td>
</tr>
<tr>
<td>7</td>
<td>Road traffic accidents</td>
<td>292 481</td>
<td>3.29</td>
</tr>
<tr>
<td>8</td>
<td>Esophageal cancer</td>
<td>212 537</td>
<td>2.39</td>
</tr>
<tr>
<td>9</td>
<td>Other injuries</td>
<td>209 836</td>
<td>2.36</td>
</tr>
<tr>
<td>10</td>
<td>Hypertension</td>
<td>205 689</td>
<td>2.31</td>
</tr>
</tbody>
</table>

**TREATMENT: NO WINNERS**

Current treatment for GERD patients includes acid suppressive medications and lower esophageal repair surgery. Aside from traditional antacids (Alka-Seltzer and Tums) which have side effects such as diarrhea and constipation, there are now two categories of medications to treat GERD. H-2 blockers (e.g., Zantac 75, Pepcid AC, Tagamet HB and Axid AR) reduce the amount of histamine-2, which produces acid in the stomach, and are recommended for people with less frequent/severe heartburn. A second medication is the proton pump inhibitors or proton pump inhibitors (PPIs) (e.g., Prilosec, Prevacid, Protonix and Nexium), which directly shuts down the H’/K’-ATPase pump of the parietal cells in the stomach that produce acid. These drugs are stronger than H2 blockers and are recommended for people with more persistent/acute symptoms. Control of acid reflux with PPIs has been found extremely effective for healing reflux esophagitis, but not for prevention of BE development or its progression to EAC. As matter of fact, more and more evidence is emerging about the long-term side-effects associated with these drugs, such as decreased absorption of vitamins/minerals, susceptibility to bacterial infections, bone fracture, and even elevated risk of developing EAC. The Food and Drug Administration of the United States has issued warnings repeatedly over the years on high-dose or long-term use of PPIs.

For people who have responded to medication but continue to experience GERD symptoms, surgery to reconstruct the lower esophageal sphincter is usually an option. However, only about 5% of GERD patients undergo surgery and a follow-up study showed that almost two-thirds of the surgical patients were back on medica-
tion. A more recent study reported that although surgical therapy achieved better remission of GERD symptoms than Prilosec, 36% of surgical-treated GERD patients ultimately received PPI medication, while 14% of PPI-treated GERD patients underwent subsequent surgery. One final way to treat GERD is through endoscopic procedures, including stitching or using radio-frequency waves to reconstruct the lower esophageal sphincter, but in 2002 this was not recommended by the American Gastroenterological Association for GERD treatment.

CAUSE OF EAC: ACID OR BILE? WHAT TO BLAME?

The inadequacy of treatment options raises the question on the real scientific basis of acid suppression in GERD treatment. A direct chemical analysis of esophageal fluid showed that GERD patients contain about 10 times more bile acid in their lower esophagus than normal people. This might give us a clue as to why regular use of acid suppressants has not lowered the risk of GERD malignancy. In support of this notion, animal studies showed that gastric reflux alone does not cause EAC at all; it is the duodenal contents per se that ultimately lead to esophageal malignancy. Furthermore, some animal studies even suggested that gastric acid may play a protective role in GERD against malignancy. For example, one study showed that 87% of rats with surgically-created duodenal reflux alone developed EAC, while the percentage of rats with gastric-duodenal reflux was only 30%. In agreement with the animal studies, a recent systematic review examined publications indexed in MEDLINE from 1950 to 2010, and found 82 original human studies on the association of bile acids with GERD, among which, all in vitro studies detected bile acids in the esophageal aspirates of GERD patients, and what’s more, their concentrations were significantly higher than in normal people. It is clear that the refluxate of GERD patients frequently contains bile acids, some-times even in millimolar concentrations. In addition to human studies and animal modeling, in vitro experiments have shown that bile acids, at equivalent concentrations to the ones found in the esophagus of GERD patients, can stimulate esophageal epithelial cells to produce inflammatory cytokines and chemokines, to generate reactive oxygen species, and to express intestinal genes. All these factors have the ability to facilitate esophageal epithelial metaplasia and even malignancy.

CONCLUSION

Although skin cancer is the most common cancer in the world, 95% of cases are either basal cell carcinoma or squamous cell carcinoma, which have less than 0.5% mortality. Even for the most deadly type of skin cancer - melanoma, which is very rare - the death rate is only about 15%. So is prostate cancer, the second most common cancer in the United States. On the other hand, although esophageal cancer patients have a mortality rate of approximately 85%, since it is less common than either skin cancer or prostate cancer, it receives little attention from government agencies or the research community. This can be seen by looking at the annual budget of the National Institute of Health (NIH) of the United States. In 2011, the NIH spent $284 million on 772 prostate cancer research projects, while only funding 30 esophageal cancer studies with $13 million (Figure 5). Through this article, we hope to attract attention to this disease since, due to its high mortality and fast growth, esophageal cancer could be catastrophic in the near future if we do not prepare ourselves with the proper knowledge.

REFERENCES

7. Shaheen NJ, Hansen RA, Morgan DR, Gangarosa LM, Ringel Y, Thiny MT, Russo MW, Sandler RS. The burden of
gastrointestinal and liver diseases, 200b. Am J Gastroenterol 2006; 101: 2128-2138


9 Lagergren J. Adenocarcinoma of the oesophagus: what exactly is the size of the problem and who is at risk? Gut 2005; 54 Suppl 1: i1-i5

10 Corley DA. Obesity and the rising incidence of oesophageal and gastric adenocarcinoma: what is the link? Gut 2007; 56: 1493-1494


18 Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 2619-2628


22 Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastriccardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 872-878


25 Wu JC, Mui LM, Cheung CM, Chan Y, Sung JJ. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology 2007; 132: 885-889


32 Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-2953

33 Leedham S, Jankowski J. The evidence base of proton pump inhibitor chemopreventative agents in Barrett's oesophagus-the good, the bad, and the flawed! Am J Gastroenterol 2007; 102: 21-23


36 Kauer WK, Peters JH, DeMeester TR, Feussner H, Ireland AP, Stein HJ, Sievert RJ. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery 1997; 122: 874-881


40 Ireland AP, Peters JH, Smyrk TC, DeMeester TR, Clark GW, Mirvish SS, Adrian TE. Gastric juice protects against the development of esophageal adenocarcinoma in the rat. Am J Gastroenterol 2000; 95: 224: 358-370; discussion 370-371


42 Thompson R. Upper gastrointestinal tract: Bile acids may have a role in G ERD and related neoplasia. Nat Rev Gastroenterol Hepatol 2011; 8: 419

S-Editor Wu X L-Editor Rutherford A E-Editor LJY